Standard BioTools (NASDAQ:LAB) Posts Quarterly Earnings Results, Hits Estimates

Standard BioTools (NASDAQ:LAB - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07), Zacks reports. The firm had revenue of $46.72 million during the quarter, compared to the consensus estimate of $43.03 million. Standard BioTools had a negative return on equity of 27.05% and a negative net margin of 79.92%. Standard BioTools updated its FY 2025 guidance to EPS.

Standard BioTools Stock Performance

Standard BioTools stock traded up $0.02 during trading on Friday, reaching $1.07. 8,064,049 shares of the company's stock were exchanged, compared to its average volume of 2,103,859. The company's 50-day moving average is $1.60 and its two-hundred day moving average is $1.80. Standard BioTools has a 52-week low of $1.00 and a 52-week high of $3.04. The firm has a market cap of $396.46 million, a price-to-earnings ratio of -1.50 and a beta of 1.57.

Analysts Set New Price Targets

Separately, KeyCorp cut Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.